BIO-key Demonstrates Award-Winning Biometric-Enhanced Cybersecurity Solutions at ScanSource Channel Connect Conference in Nashville Oct. 2-5

NASHVILLE, Tenn. and WALL, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: BKYI), an innovative provider of Identity and Access Management (IAM) and Identity-Bound Biometric (IBB) solutions, today announced it will demonstrate its solutions and meet with partner prospects at (Booth 205) in Nashville, TN, October 2–5. ScanSource Channel Connect combines for the first time the ScanSource Partner Conference and Intelisys Channel Connect to create an even greater opportunity for partners and suppliers to gain knowledge, strengthen relationships, and create new partnerships. BIO-key is the exclusive IAM provider for , the nation’s leading distributor of IT solutions and services and a ScanSource company.

BIO-key will demonstrate its IAM platform and , its one-of-a-kind, multi-factor authentication mobile app with new and enhanced Identity-Bound Biometric capabilities. BIO-key solutions make it easy for partners to address their customers’ most pressing cybersecurity requirements and competitively differentiate their business. BIO-key seeks to further expand its within the Intelisys partner community by demonstrating the substantial revenue opportunities and customer value its solutions provide.

“Despite the rise in cyberattacks, the market for IAM is far from saturated – and expected to grow at a 14.5% compound annual rate to more than ,” said Fred Corsentino, Chief Revenue Officer of BIO-key, “creating a significant revenue opportunity for BIO-key and our global partner network. We look forward to informing partners and suppliers about how to use BIO-key’s differentiated solutions to create profitable and long-lasting customer relationships.”

Stop by booth 205 to learn about BIO-key’s award-winning cybersecurity solutions and how partnering with BIO-key can:

• Differentiate your cybersecurity portfolio with Identity-Bound Biometrics;
• Build a new strong recurring revenue stream for your business;
• Help your customers reduce cyber risk & meet cyber insurance requirements;
• Provide an IAM solution that beats the competition in both features and price; and
• Enhance your expertise and position as a trusted cybersecurity advisor.
  
  

BIO-key’s award-winning PortalGuard IAM platform has been implemented by 1,000+ customers worldwide to consolidate security applications under a single, unified solution, reducing overhead and improving productivity for users and the IT team. PortalGuard is recognized for its flexible options for multi-factor authentication (MFA), single sign-on, and self-service password reset, with exclusive Identity-Bound Biometric authentication that provides the highest levels of risk reduction, flexibility, and cost efficiency. For enterprises dealing with passwordless workflows, remote workforces, and customer IAM, BIO-key’s MobileAuth MFA mobile app enables users to authenticate with Identity-Bound Biometrics on any mobile device, eliminating the risks and high costs associated with traditional authentication methods.

For more information about 2022 ScanSource Channel Connect, please visit the . To learn more about BIO-key’s IAM solutions and CAP Program, please visit .

About BIO-key International, Inc. ()

BIO-key has over two decades of expertise in providing authentication technology for thousands of organizations and millions of users and is revolutionizing authentication with biometric-centric, multi-factor identity and access management (IAM) solutions, including its PortalGuard IAM solution, that provides convenient and secure access to devices, information, applications, and high-value transactions. BIO-key's patented software and hardware solutions, with industry-leading biometric capabilities, enable large-scale on-premises and cloud-based Identity-as-a-Service (IDaaS) solutions, as well as customized enterprise solutions.

BIO-key Safe Harbor Statement

All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; the duration and severity of the current coronavirus COVID-19 pandemic and its effect on our business operations, sales cycles, personnel, and the geographic markets in which we operate; delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption see "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the Company undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise. Additionally, there may be other factors of which the Company is not currently aware that may affect matters discussed in forward-looking statements and may also cause actual results to differ materially from those discussed. In particular, the consequences of the coronavirus outbreak to economic conditions and the industry in general and the financial position and operating results of our Company, in particular, have been material, are changing rapidly, and cannot be predicted.

Engage with BIO-key

Facebook – Corporate:   

LinkedIn – Corporate:   

Twitter – Corporate:

Twitter – Investors:

StockTwits:

Media Contact

Erin Knapp

Matter on behalf of BIO-key

  

Investor Contacts

William Jones, David Collins

Catalyst IR

  

212-924-9800